Molecular target for preparing drugs for treating TFE3 gene rearrangement renal cell carcinoma and its use

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
By interfering with the LGI3 gene to inhibit the proliferation, migration and invasion of TFE3 rearranged renal cell carcinoma, the problem of lack of effective treatment in this type of cancer is solved and a potential therapeutic target is provided.

CN119372210BActive Publication Date: 2025-03-18THE THIRD MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL

0 Cites 0 Cited by

Patent Information

Application Number: CN202411945597.7
Authority / Receiving Office: CN · China
Patent Type: Patents(China)
Current Assignee / Owner
Filing Date: 2024-12-27
Publication Date: 2025-03-18
Estimated Expiration: 2044-12-27

Application Information

Patent Timeline

27 Dec 2024

Application

CN202411945597.7

18 Mar 2025

Publication

CN119372210B

IPC: C12N15/12; A61K45/00; A61P35/00; A61P13/12

CPC: A61K45/00; A61P35/00; A61P13/12; C07K14/4705

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Peptides Urinary disorder

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

TFE3 gene rearrangement renal cell carcinoma has a high degree of malignancy, poor clinical prognosis, and lacks universal and effective treatment methods.

Method used

The LGI3 gene is used as a molecular target to inhibit the proliferation, migration and invasion of TFE3 rearranged renal cell carcinoma by interfering with the LGI3 gene.

Benefits of technology

Interference with LGI3 can effectively inhibit the proliferation, migration and invasion of TFE3 rearranged renal cell carcinoma, providing a potential therapeutic target.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The present invention provides a molecular target for preparing a drug for treating TFE3 gene rearrangement renal cell carcinoma and its use, and relates to the field of biomedicine technology. The molecular target is the LGI3 gene, and the base sequence of the LGI3 gene is: SEQ ID No. 1. In the present invention, after interfering with LGI3, the proliferation, migration and invasion ability of TFE3 rearrangement renal cell carcinoma can be effectively inhibited, so the LGI3 gene is expected to be used as a molecular target in the treatment of clinical TFE3 rearrangement renal cell carcinoma patients.

Need to check novelty before this filing date? Find Prior Art